Categories: NewsPharmaceutical

Harvard Bioscience Schedules First Quarter 2024 Earnings Conference Call for May 7, 2024 at 8:00 AM ET

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

HOLLISTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2024 before the market opens on May 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. 

Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. 

Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here.

Financial information presented on the call, including the earnings release and a related slide presentation, will be available on the Investor Relations section of Harvard Bioscience’s website. 

About Harvard Bioscience 

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.

Company Contact:
Jennifer Cote
Chief Financial Officer
(508) 893-3120

Investors Contact:
Three Part Advisors
Sandy Martin / Erol Girgin / William Shelmire
HBIO@threepa.com
(214) 616-2207

Staff

Recent Posts

Next Step Healthcare Notifies Individuals of Data Security Incident

WOBURN, Mass., May 29, 2025 /PRNewswire/ -- Next Step Healthcare, LLC ("Next Step") is providing…

3 hours ago

Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering

Philadelphia, Pennsylvania--(Newsfile Corp. - May 29, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company")…

6 hours ago

Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine

Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next…

9 hours ago

Care Career, Inc. Acquires Four Leading Healthcare Staffing Firms in Strategic Growth Move

LAS VEGAS, May 29, 2025 /PRNewswire/ -- Care Career, Inc. (www.carecareer.com) today announced it has…

9 hours ago

Medcrypt Expands Platform Capabilities as Demand for Medical Device Cybersecurity Solutions Surges

New Product Launch, Enterprise Momentum, and Industry Partnerships Fuel Medcrypt's Growth in 2025 SAN DIEGO,…

9 hours ago